As Novo Nordisk’s patent expires on March 20, Sun Pharma, Dr Reddy’s, Zydus and Mankind enter the market after months of ...

Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent ...

Generic drugmakers in India launch affordable Semaglutide versions, targeting a $1 billion diabetes and weight loss market.

Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an add-on to the ...

Zydus Lifesciences Limited, an innovation-led global life-sciences company and Torrent Pharmaceuticals Limited, a ...

Sun Pharma and Zydus Lifesciences launch affordable generics of semaglutide in India for weight management and diabetes treatment.

March 17 () - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply ‌deal on Tuesday to co‑market ...

Torrent Pharmaceuticals has launched India's first generic oral semaglutide, Sembolic, and an injectable version, Semalix, priced at ₹3,999 per month.

With low dose starting at 1,290 per month, analysts are expecting a two-fold jump in the sale of GLP-1 units over the next three months due to the steep price cuts.

Zydus Lifesciences and Torrent Pharmaceuticals have inked a licensing and supply agreement to co-market diabetes treatment medication Semaglutide Injection in the Indian market. U ...

Under the Licensing and Supply Agreement signed by both companies, Lupin will have semi-exclusive rights to co-market Zydus’ ...

Following the patent expiry of semaglutide in India, leading pharma companies including Sun Pharma, Dr Reddy’s, Zydus, and ...